Claims for Patent: 7,884,196

Summary for Patent: 7,884,196

Title:	Vaccine composition comprising methylated DNA and immunomodulatory motifs
Abstract:	The present invention relates generally to compositions and methods using mammalian, dsDNA (Double Stranded Deoxyribonucleic Acid) vaccination for the induction and maintenance of regulator suppressor T cells resulting in suppression of non infectious, and post infectious, inflammatory, allergic, auto-immune, vasculitic, certain degenerative vascular, and graft versus host diseases, with or without the use of IL-10, and with or without the use or TGF.beta., with or without the use of anti-IL 6 receptor antibody, anti TNF antibody and or Plasmapheresis, IVIG, Corticosteroids, Methotrexate, Bromocriptine, and or vitamin D analogues.
Inventor(s):	Lawless; Oliver (Highland, MD)
Assignee:	Lawless; Oliver (Olney, MD)
Application Number:	11/244,142
Patent Claims:	1. A vaccine composition for treating inflammatory, non infectious and/or post infectious, allergic, autoimmune, vasculitic, degenerative vascular, host v graft, graft v host diseases, Alzheimer's Disease, and amyloidosis comprising: a suppressor-regulator T cell activating amount of a synthetic, methylated DNA sequence of about 10 k to about 50 k Daltons, containing at least one SEQ ID NO 1 sequence and at least one SEQ ID NO 2 sequence. 2. The vaccine composition, according to claim 1, wherein said DNA is double-stranded. 3. The vaccine composition, according to claim 1, further comprising at least one agent selected from the group consisting of cytokines, antibodies, anti-TNF.alpha. biologics, and immunosuppressive agents. 4. The vaccine composition, according to claim 3, wherein said cytokine is chosen from the group consisting of IL-10 and TGF.beta. 5. The vaccine composition, according to claim 3, wherein said anti-TNF.alpha. biologics are chosen from the group consisting of Etanercept/Enbrel, Infliximab/Remicade, and Humira. 6. The vaccine composition, according to claim 3, wherein said immunosuppressive agent is chosen from the group consisting of Corticosteroids, Methotrexate, Bromocriptine, Immuran Cellcept, and vitamin D analogues. 7. A vaccine comprising: a suppressor-regulator T cell activating amount of a synthetic DNA molecule, said DNA molecule further comprising: At least one methylated region; at least one SEQ ID NO 1 sequence; and at least one SEQ ID NO 2 sequence.

Details for Patent 7,884,196

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2024-10-06
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2024-10-06
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2024-10-06